450 related articles for article (PubMed ID: 16713027)
1. [Recent advances in the treatment of myelodysplastic syndromes].
Gelsi-Boyer V; Vey N
Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027
[TBL] [Abstract][Full Text] [Related]
2. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
3. New agents in myelodysplastic syndromes.
Jabbour EJ; Giles FJ
Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplasia: when to treat and how.
Larson RA
Best Pract Res Clin Haematol; 2006; 19(2):293-300. PubMed ID: 16516126
[TBL] [Abstract][Full Text] [Related]
5. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
Stankov K; Stankov S; Katanic J
Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
[TBL] [Abstract][Full Text] [Related]
6. The myelodysplastic syndromes: the era of understanding.
Meers S
Eur J Haematol; 2015 May; 94(5):379-90. PubMed ID: 25186093
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndromes.
Hofmann WK; Lübbert M; Hoelzer D; Phillip Koeffler H
Hematol J; 2004; 5(1):1-8. PubMed ID: 14745424
[TBL] [Abstract][Full Text] [Related]
8. Treating myelodysplastic syndromes.
Ryan C; McCann S
IDrugs; 2005 Apr; 8(4):320-6. PubMed ID: 15800807
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic syndrome hematopoietic stem cell.
Li J
Int J Cancer; 2013 Aug; 133(3):525-33. PubMed ID: 23047726
[TBL] [Abstract][Full Text] [Related]
10. Evolving treatment options of myelodysplastic syndromes.
Verbeek W; Ganser A
Ann Hematol; 2001 Sep; 80(9):499-509. PubMed ID: 11669297
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic syndromes: From pathogenesis and prognosis to treatment.
Fenaux P
Semin Hematol; 2004 Apr; 41(2 Suppl 4):6-12. PubMed ID: 15190510
[TBL] [Abstract][Full Text] [Related]
12. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic strategies: hypomethylating agents and beyond.
Santini V
Hematology Am Soc Hematol Educ Program; 2012; 2012():65-73. PubMed ID: 23233562
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic Syndromes: Diagnosis and Treatment.
Steensma DP
Mayo Clin Proc; 2015 Jul; 90(7):969-83. PubMed ID: 26141335
[TBL] [Abstract][Full Text] [Related]
15. New agents in myelodysplastic syndromes.
Jabbour E; Giles FJ
Curr Hematol Malig Rep; 2006 Mar; 1(1):25-33. PubMed ID: 20425328
[TBL] [Abstract][Full Text] [Related]
16. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
17. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.
Abou Zahr A; Bernabe Ramirez C; Wozney J; Prebet T; Zeidan AM
Expert Rev Hematol; 2016; 9(4):377-88. PubMed ID: 26734762
[TBL] [Abstract][Full Text] [Related]
18. Treatment of adult myelodysplastic syndromes.
Hellström-Lindberg E
Int J Hematol; 1999 Oct; 70(3):141-54. PubMed ID: 10561906
[TBL] [Abstract][Full Text] [Related]
19. [Myelodysplastic syndromes in adults].
Beyne-Rauzy O; Laurent G; Adoue D
Presse Med; 2007 Mar; 36(3 Pt 2):481-91. PubMed ID: 17336857
[TBL] [Abstract][Full Text] [Related]
20. [Myelodysplastic syndromes--an overview for the practitioner].
Solenthaler M; Tobler A
Ther Umsch; 2004 Feb; 61(2):117-24. PubMed ID: 15018394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
